Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Italian firm's technology could support the development of more effective drugs for children in disease-endemic countries
February 6, 2020
By: Tiffany Coppolino
Indena, an Italian company that provides identification, development and production of high-quality active principles derived from plants, for use in the pharmaceutical, health-food and cosmetic industries, received a grant from the Bill & Melinda Gates Foundation to work on a strategic project to improve new potential antimalarial therapies for children in disease-endemic countries. Indena will work on a feasibility study using their proprietary technology to improve pediatric formulations of two antimalarial compounds from the portfolio of Medicines for Malaria Venture (MMV), in order to potentially improve their bioavailability. It has been challenging to develop suitable oral formulations for the two compounds in question, and it is hoped the new technology will help overcome these challenges. MMV is a leading product development partnership in the field of antimalarial drug research and development. It was established as a foundation in 1999 with a mission to reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs. Today, MMV manages the largest portfolio of antimalarial R&D projects ever assembled with its partners and counts the Bill & Melinda Gates Foundation among its long-standing partners and donors. According to the World Health Organization (WHO) World Malaria Report 2019, malaria remains a public health imperative. In 2018, 405,000 deaths were estimated worldwide and 67% of the deaths occurred in children younger than 5 years. Furthermore, 11 million pregnant women exposed to malarial infections delivered around 872,000 children with low birthweight. One of the biggest challenges in developing new antimalarials is to make sure that they have high bioavailability and to minimize the variability seen between different patients. For the two compounds in question, difficulties in getting the drugs absorbed, and high variability, has, to date, prevented them from being tested further in clinical development. “We’re very happy and proud to be part of such an important project devoted to improve pharmaceutical tools against malaria and to help people have better health conditions in Africa and other countries,” said Daniele Giavini, managing director, Indena. “Our commitment to quality and innovation is part of our history and experience. Applying that to such a worthwhile yet challenging goal through such a prestigious partnership is the best way to give even more sense to our daily work. We thank the Bill & Melinda Gates Foundation for choosing and trusting Idena.” The project started in late 2019.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !